The company owns assets related to the investigational drug product and manufacturing technology. The manufacturing process of CellProtect encompasses a unique closed system for the development of the autologous NK cell-based investigational drug product.

The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. The NK cell product is delivered to the clinic upon need, where the product is thawed and infused to the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen. The assets of XNK Therapeutics are protected by patents in the US, Europe, and certain other jurisdictions. Additional patent applications have been filed. The patented technology and investigational drug product have been tested in a first-in-human Phase I/II clinical trial.